E-DRUG: Rofecoxib (Vioxx) withdrawal
------------------------------------
I would like to bring to your attention the July/October 2004 issue (#53) of
the Therapeutics Letter: "Rofecoxib (Vioxx) withdrawal generates
uncertainty about COX-2s. Do product monographs adequately inform?" that
has just been published on the Therapeutics Initiative web-site at
http://www.ti.ubc.ca/pages/letter53.htm
In this Letter we assess how well product monographs inform clinicians,
using the COX-2s as example.
I invite you to drop by and have a look at this Letter. Please feel free to
forward this message to any of your friends or colleagues that might be
interested in this topic.
We would appreciate receiving your comments on this Therapeutics Letter and
its possible implications in clinical practice.
Best regards,
Ciprian Jauca
Manager
Therapeutics Initiative
University of British Columbia
Department of Pharmacology & Therapeutics
2176 Health Sciences Mall
Vancouver, BC V6T 1Z3
Canada
Email: jauca@ti.ubc.ca
Tel: +1 (604) 822-0700
Fax: +1 (604) 822-0701
Web: www.ti.ubc.ca